Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Key Inclusion Criteria: * Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer * Complete or partial response following standard of care surgery and first line chemotherapy * May have one disease recurrence with complete or partial response or stable disease following standard of care second line care treatment * Previous investigational biologic therapy allowed, must be more than 56 days prior to first injection * Previous treatment with bisphosphonate allowed, must be completed 14 days prior to first injection * Ambulatory with an ECOG 0-1 * Life expectancy \> 6 months * Meet protocol-specified lab requirements * Provide informed consent and have ability to comply with protocol requirements Key Exclusion Criteria: * Concurrent chemotherapy, radiation therapy, immunotherapy are excluded (washout periods as specified in protocol) * Prior receipt of survivin based vaccines * Participation in prior therapeutic adjuvant ovarian cancer studies, except for platinum-based adjuvant studies * Progressive disease (rising CA-125 acceptable) * More than one course of chemotherapy for recurrent disease * Concurrent bevacizumab as maintenance therapy * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * History of autoimmune disease * Recent history of thyroiditis * Presence of a serious acute infection or chronic infection * Brain metastases * Other serious intercurrent chronic or acute illness * Ongoing treatment with steroid therapy or other immunosuppressive * Acute or chronic skin disorders